PAMELA PRICE: Open Payments
NPI 1346226636 · SALEM, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,529 in 53 payments from 12 companies in 2025. Trend: 2023 $3,233 · 2024 $1,492 · 2025 $3,529
Honoraria: $1,500Food & beverage: $1,137Consulting: $893
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 5 | $2,457 |
| AstraZeneca Pharmaceuticals LP | 13 | $275 |
| GENZYME CORPORATION | 11 | $255 |
| Regeneron Healthcare Solutions, Inc. | 10 | $137 |
| Novartis Pharmaceuticals Corporation | 5 | $88 |
| Genentech USA, Inc. | 1 | $75 |
| BioCryst US Sales Co., LLC | 2 | $72 |
| GlaxoSmithKline, LLC. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $51 |
| CSL Behring | 1 | $26 |
Products named: DUPIXENT, AIRSUPRA, XOLAIR, AYVAKIT, TEZSPIRE, ORLADEYO, BREZTRI, NUCALA.
Industry payments across VA — which companies pay providers there.
